Safety and Immunogenicity of EXG-5003

NCT04863131 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: EXG-5003
BIOLOGICAL: Placebo

Sponsor

Fujita Health University

Collaborators

[object Object]